Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lasioglossins LLIII affect the morphogenesis of Candida albicans and reduces the duration of experimental vaginal candidiasis in mice

A. Vrablikova, L. Czernekova, R. Cahlikova, Z. Novy, M. Petrik, S. Imran, Z. Novak, M. Krupka, V. Cerovsky, J. Turanek, M. Raska,

. 2017 ; 61 (11) : 474-481. [pub] 20171024

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024662

Lasioglossins are a group of peptides with identified antimicrobial activity. The inhibitory effects of two synthetic lasioglossin derivatives, LLIII and D-isomeric variant LLIII-D, on morphological changes in Candida albicans in vitro and the effect of local administration of LLIII during experimental murine candidiasis were investigated. C. albicans blastoconidia were grown in the presence of lasioglossin LLIII or LLIII-D at concentrations of 11.5 μM and 21 μM, respectively, for 1, 2 and 3 days and their viability determined by flow cytometry using eosin Y staining. Morphological changes were examined by light and fluorescent microscopy. The Candida-inhibitory effect of daily intravaginal administration of 0.7 or 1.4 μg of LLIII was assessed in mice with experimentally-induced vaginal candidiasis. LLIII and LLIII-D lasioglossins exhibited candidacidal activity in vitro (>76% after 24 hr and >84% after 48 hr of incubation). After 72 hr incubation of Candida with low concentration of lasioglossins, an increase in viability was detected, probably due to a Candida antimicrobial peptides evasion strategy. Furthermore, lasioglossins inhibited temperature-induced morphotype changes toward hyphae and pseudohyphae with sporadic occurrence of atypical cells with two or enlarged nuclei, suggesting interference with mitosis or cytokinesis. Local application of LLIII reduced the duration of experimental candidiasis with no evidence of adverse effects. Lasioglossin LLIII is a promising candidate for development as an antimicrobial drug for treating the vaginal candidiasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024662
003      
CZ-PrNML
005      
20180718113752.0
007      
ta
008      
180709s2017 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1348-0421.12538 $2 doi
035    __
$a (PubMed)28892177
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Vrablikova, Alena $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
245    10
$a Lasioglossins LLIII affect the morphogenesis of Candida albicans and reduces the duration of experimental vaginal candidiasis in mice / $c A. Vrablikova, L. Czernekova, R. Cahlikova, Z. Novy, M. Petrik, S. Imran, Z. Novak, M. Krupka, V. Cerovsky, J. Turanek, M. Raska,
520    9_
$a Lasioglossins are a group of peptides with identified antimicrobial activity. The inhibitory effects of two synthetic lasioglossin derivatives, LLIII and D-isomeric variant LLIII-D, on morphological changes in Candida albicans in vitro and the effect of local administration of LLIII during experimental murine candidiasis were investigated. C. albicans blastoconidia were grown in the presence of lasioglossin LLIII or LLIII-D at concentrations of 11.5 μM and 21 μM, respectively, for 1, 2 and 3 days and their viability determined by flow cytometry using eosin Y staining. Morphological changes were examined by light and fluorescent microscopy. The Candida-inhibitory effect of daily intravaginal administration of 0.7 or 1.4 μg of LLIII was assessed in mice with experimentally-induced vaginal candidiasis. LLIII and LLIII-D lasioglossins exhibited candidacidal activity in vitro (>76% after 24 hr and >84% after 48 hr of incubation). After 72 hr incubation of Candida with low concentration of lasioglossins, an increase in viability was detected, probably due to a Candida antimicrobial peptides evasion strategy. Furthermore, lasioglossins inhibited temperature-induced morphotype changes toward hyphae and pseudohyphae with sporadic occurrence of atypical cells with two or enlarged nuclei, suggesting interference with mitosis or cytokinesis. Local application of LLIII reduced the duration of experimental candidiasis with no evidence of adverse effects. Lasioglossin LLIII is a promising candidate for development as an antimicrobial drug for treating the vaginal candidiasis.
650    _2
$a aplikace intravaginální $7 D000282
650    _2
$a zvířata $7 D000818
650    _2
$a antifungální látky $x aplikace a dávkování $7 D000935
650    _2
$a kationické antimikrobiální peptidy $x aplikace a dávkování $7 D023181
650    _2
$a Candida albicans $x účinky léků $x růst a vývoj $7 D002176
650    _2
$a kandidóza vulvovaginální $x farmakoterapie $x mikrobiologie $7 D002181
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední DBA $7 D008811
655    _2
$a časopisecké články $7 D016428
700    1_
$a Czernekova, Lydie $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
700    1_
$a Cahlikova, Romana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
700    1_
$a Novy, Zbynek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
700    1_
$a Petrik, Milos $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
700    1_
$a Imran, Saima $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
700    1_
$a Novak, Zdenek $u Department of Surgery, University of Alabama at Birmingham, BDB 503, 18th St. So., 35294, Birmingham, Alabama, USA.
700    1_
$a Krupka, Michal $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic.
700    1_
$a Cerovsky, Vaclav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo náměstí 542/2, 166 10 Praha, Czech Republic.
700    1_
$a Turanek, Jaroslav $u Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 296/70, 621 00 Brno, Czech Republic.
700    1_
$a Raska, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 772 00 Olomouc, Czech Republic. Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 296/70, 621 00 Brno, Czech Republic.
773    0_
$w MED00003343 $t Microbiology and immunology $x 1348-0421 $g Roč. 61, č. 11 (2017), s. 474-481
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28892177 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180718114052 $b ABA008
999    __
$a ok $b bmc $g 1316793 $s 1021583
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 61 $c 11 $d 474-481 $e 20171024 $i 1348-0421 $m Microbiology and immunology $n Microbiol Immunol $x MED00003343
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace